• In late March 2026, Hims & Hers Health announced a renewed collaboration with Novo Nordisk, adding a broad range of FDA-approved GLP-1 medications, including Wegovy weight loss pills and injections, plus Ozempic for Type 2 diabetes, to its telehealth platform with memberships starting at US$39 for the first month and medication prices from US$149 a month.
• The partnership deepens Hims & Hers’ push into medically supervised weight management by pairing branded GLP-1 access with ongoing virtual care, nutrition guidance, community support, and, where clinically necessary, compounded GLP-1 options for a limited group of patients whose needs are not met by commercial therapies.
• We’ll now explore how this expanded GLP-1 access with Novo Nordisk could influence Hims & Hers’ investment narrative around growth, risk, and profitability.

Outshine the giants: these 20 early-stage AI stocks could fund your retirement.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers, you need to believe it can convert telehealth demand for lifestyle and chronic care into profitable, recurring subscriptions across weight loss, sexual health, and labs. The expanded Novo Nordisk GLP-1 lineup ties directly into the most important near term catalyst: deepening weight management adoption on-platform. At the same time, the recent customer service data breach underlines one of the biggest current risks around data security and rising regulatory and legal scrutiny.

Among recent developments, the February 2026 disclosure of a social engineering attack on a third party support platform matters most here, because it sits at the intersection of growth and risk. As Hims & Hers enlarges its GLP-1 and membership footprint with Novo Nordisk, any questions around privacy, class action exposure, or regulatory reaction could influence marketing efficiency, customer trust, and ultimately how much of that weight loss opportunity it captures.

But while the GLP-1 relaunch grabs headlines, investors should also be aware of the emerging data privacy and regulatory risk around...

Hims & Hers Health's narrative projects $3.6 billion revenue and $248.5 million earnings by 2029. This requires 15.6% yearly revenue growth and about a $120 million earnings increase from $128.4 million today.

Uncover how Hims & Hers Health's forecasts yield a $24.15 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$4.1 billion of revenue and roughly US$331.6 million of earnings by 2028, while also flagging tight regulatory and privacy risk around lab testing and GLP 1s; this Novo Nordisk news could either reinforce that bull case or expose why reasonable investors might see the story very differently.

Explore 55 other fair value estimates on Hims & Hers Health - why the stock might be worth over 8x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• Find 61 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.